JP7660135B2 - Tyk2阻害剤の結晶形態 - Google Patents

Tyk2阻害剤の結晶形態 Download PDF

Info

Publication number
JP7660135B2
JP7660135B2 JP2022559959A JP2022559959A JP7660135B2 JP 7660135 B2 JP7660135 B2 JP 7660135B2 JP 2022559959 A JP2022559959 A JP 2022559959A JP 2022559959 A JP2022559959 A JP 2022559959A JP 7660135 B2 JP7660135 B2 JP 7660135B2
Authority
JP
Japan
Prior art keywords
compound
formula
mixture
crystal
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521631A5 (cg-RX-API-DMAC7.html
JP2023521631A (ja
Inventor
チャールズ リーダー、ジョン
コナー マーシャル、ジェイミー
ミキテューク、ジョン
スコット ノーゼン、ジュリアン
Original Assignee
サリウム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サリウム リミテッド filed Critical サリウム リミテッド
Publication of JP2023521631A publication Critical patent/JP2023521631A/ja
Publication of JP2023521631A5 publication Critical patent/JP2023521631A5/ja
Application granted granted Critical
Publication of JP7660135B2 publication Critical patent/JP7660135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022559959A 2020-04-07 2021-04-06 Tyk2阻害剤の結晶形態 Active JP7660135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
GB2005114.0 2020-04-07
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor

Publications (3)

Publication Number Publication Date
JP2023521631A JP2023521631A (ja) 2023-05-25
JP2023521631A5 JP2023521631A5 (cg-RX-API-DMAC7.html) 2024-04-01
JP7660135B2 true JP7660135B2 (ja) 2025-04-10

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559959A Active JP7660135B2 (ja) 2020-04-07 2021-04-06 Tyk2阻害剤の結晶形態

Country Status (11)

Country Link
US (2) US12545652B2 (cg-RX-API-DMAC7.html)
EP (1) EP4132649A1 (cg-RX-API-DMAC7.html)
JP (1) JP7660135B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220164751A (cg-RX-API-DMAC7.html)
CN (1) CN115515683B (cg-RX-API-DMAC7.html)
BR (1) BR112022016359A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167172A1 (cg-RX-API-DMAC7.html)
GB (1) GB202005114D0 (cg-RX-API-DMAC7.html)
IL (1) IL296989A (cg-RX-API-DMAC7.html)
MX (1) MX2022011593A (cg-RX-API-DMAC7.html)
WO (1) WO2021204762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
JP2025510826A (ja) * 2022-03-25 2025-04-15 武田薬品工業株式会社 Tyk2阻害剤の固体形態及び使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529264A (ja) 2013-09-03 2016-09-23 サリウム リミテッド 医薬化合物
WO2018073438A1 (en) 2016-10-21 2018-04-26 Sareum Limited Pharmaceutical compounds
JP2022514799A (ja) 2018-10-08 2022-02-15 サリウム リミテッド Tyk2キナーゼ阻害剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG11201401342VA (en) 2011-10-12 2014-09-26 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
ES2566205T3 (es) 2012-03-02 2016-04-11 Sareum Limited Inhibidores de quinasa TYK2
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529264A (ja) 2013-09-03 2016-09-23 サリウム リミテッド 医薬化合物
WO2018073438A1 (en) 2016-10-21 2018-04-26 Sareum Limited Pharmaceutical compounds
JP2022514799A (ja) 2018-10-08 2022-02-15 サリウム リミテッド Tyk2キナーゼ阻害剤

Also Published As

Publication number Publication date
AU2021253128A1 (en) 2022-08-25
GB202005114D0 (en) 2020-05-20
KR20220164751A (ko) 2022-12-13
EP4132649A1 (en) 2023-02-15
MX2022011593A (es) 2022-10-18
CA3167172A1 (en) 2021-10-14
US20230159473A1 (en) 2023-05-25
IL296989A (en) 2022-12-01
BR112022016359A2 (pt) 2022-10-04
CN115515683A (zh) 2022-12-23
WO2021204762A1 (en) 2021-10-14
CN115515683B (zh) 2024-10-25
US20260217664A1 (en) 2026-07-30
US12545652B2 (en) 2026-02-10
JP2023521631A (ja) 2023-05-25

Similar Documents

Publication Publication Date Title
US11673870B2 (en) Pharmaceutical compounds
JP6239118B2 (ja) 医薬化合物
US12545652B2 (en) Crystalline forms of a TYK2 inhibitor
JP7383030B2 (ja) Tyk2キナーゼ阻害剤
RU2805932C2 (ru) Фармацевтические соединения
HK40048146A (en) Tyk2 kinase inhibitors
HK40048146B (en) Tyk2 kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250331

R150 Certificate of patent or registration of utility model

Ref document number: 7660135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150